Actuate Therapeutics (ACTU) Earnings Date & Reports

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3)... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

ACTU is expected to report earnings to rise 75.00% to -34 cents per share on December 02

Actuate Therapeutics ACTU Stock Earnings Reports

Q3'26

Est.

$-0.35

Q2'26

Beat

by $0.13

Q1'26

Beat

by $0.07

Q4'25

Beat

by $0.01

Q3'25

Missed

by $0.07

The last earnings report on September 02 showed earnings per share of -20 cents, beating the estimate of -33 cents. With 124.50K shares outstanding, the current market capitalization sits at 25.58M.

View a ticker or compare two or three

ACTU

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading for ACTU